95 related articles for article (PubMed ID: 27016178)
1. Comparison of three quantification methods for the TZM-bl pseudovirus assay for screening of anti-HIV-1 agents.
Xing L; Wang S; Hu Q; Li J; Zeng Y
J Virol Methods; 2016 Jul; 233():56-61. PubMed ID: 27016178
[TBL] [Abstract][Full Text] [Related]
2. Development of a pseudovirus assay and evaluation to screen natural products for inhibition of HIV-1 subtype C reverse transcriptase.
Mavhandu LG; Cheng H; Bor YC; Tebit DM; Hammarskjold ML; Rekosh D; Bessong PO
J Ethnopharmacol; 2020 Aug; 258():112931. PubMed ID: 32360797
[TBL] [Abstract][Full Text] [Related]
3. Anti-HIV-1 activity determined by β-galactosidase activity in the multinuclear activation of an indicator assay is comparable with that by a conventional focus counting method.
Miyamoto F; Kawaji K; Oishi S; Fujii N; Kaku M; Kodama EN
Antivir Chem Chemother; 2015 Apr; 24(2):77-82. PubMed ID: 26527820
[TBL] [Abstract][Full Text] [Related]
4. Superiority of infectivity-based over particle-based methods for quantitation of drug resistant HIV-1 as inocula for cell cultures.
Tschochner M; Schwingel E; Thein C; Wittmann S; Paatz C; Walter H
J Virol Methods; 2007 Apr; 141(1):87-96. PubMed ID: 17196267
[TBL] [Abstract][Full Text] [Related]
5. [Using reporter gene to compare infection efficiency of HIV-1 pseudovirus to suspended and adherent cells].
Su Y; Su L; Yin T; Zhang B
Wei Sheng Wu Xue Bao; 2012 Jul; 52(7):921-6. PubMed ID: 23115978
[TBL] [Abstract][Full Text] [Related]
6. A novel, cell-free PCR-based assay for evaluating the inhibitory activity of antiretroviral compounds against HIV reverse transcriptase.
Frezza C; Balestrieri E; Marino-Merlo F; Mastino A; Macchi B
J Med Virol; 2014 Jan; 86(1):1-7. PubMed ID: 24068579
[TBL] [Abstract][Full Text] [Related]
7. A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1.
Garcia-Perez J; Sanchez-Palomino S; Perez-Olmeda M; Fernandez B; Alcami J
J Med Virol; 2007 Feb; 79(2):127-37. PubMed ID: 17177310
[TBL] [Abstract][Full Text] [Related]
8. Rapid screening of phenotypic resistance to nevirapine by direct analysis of HIV type 1 reverse transcriptase activity in plasma.
Vázquez-Rosales G; García Lerma JG; Yamamoto S; Switzer WM; Havlir D; Folks TM; Richman DD; Heneine W
AIDS Res Hum Retroviruses; 1999 Sep; 15(13):1191-200. PubMed ID: 10480632
[TBL] [Abstract][Full Text] [Related]
9. Gold(I) complex of 1,1'-bis(diphenylphosphino) ferrocene-quinoline conjugate: a virostatic agent against HIV-1.
Gama N; Kumar K; Ekengard E; Haukka M; Darkwa J; Nordlander E; Meyer D
Biometals; 2016 Jun; 29(3):389-97. PubMed ID: 26922346
[TBL] [Abstract][Full Text] [Related]
10. Testing anti-HIV activity of antiretroviral agents in vitro using flow cytometry analysis of CEM-GFP cells infected with transfection-derived HIV-1 NL4-3.
Frezza C; Grelli S; Federico M; Marino-Merlo F; Mastino A; Macchi B
J Med Virol; 2016 Jun; 88(6):979-86. PubMed ID: 26519867
[TBL] [Abstract][Full Text] [Related]
11. An Enhanced Emtricitabine-Loaded Long-Acting Nanoformulation for Prevention or Treatment of HIV Infection.
Mandal S; Belshan M; Holec A; Zhou Y; Destache CJ
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821449
[TBL] [Abstract][Full Text] [Related]
12. An anti-HIV microbicide engineered in commensal bacteria: secretion of HIV-1 fusion inhibitors by lactobacilli.
Pusch O; Kalyanaraman R; Tucker LD; Wells JM; Ramratnam B; Boden D
AIDS; 2006 Oct; 20(15):1917-22. PubMed ID: 16988512
[TBL] [Abstract][Full Text] [Related]
13. A computer-based, image-analysis method to quantify HIV-1 infection in a single-cycle infectious center assay.
Day JR; Martínez LE; Sásik R; Hitchin DL; Dueck ME; Richman DD; Guatelli JC
J Virol Methods; 2006 Oct; 137(1):125-33. PubMed ID: 16876264
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of pyridinium polyoxometalates as anti-HIV-1 agents.
Wang S; Sun W; Hu Q; Yan H; Zeng Y
Bioorg Med Chem Lett; 2017 Jun; 27(11):2357-2359. PubMed ID: 28431877
[TBL] [Abstract][Full Text] [Related]
15. [Tat-based cell-cell fusion method for screening HIV-1 fusion inhibitors].
Wang X; Yang Y; Shen S; Wang X; Feng T; Hu Q; Zeng Y
Sheng Wu Gong Cheng Xue Bao; 2018 Mar; 34(3):429-439. PubMed ID: 29577693
[TBL] [Abstract][Full Text] [Related]
16. [A non-infectious and quantitative cell-based bioassay for screening HIV entry inhibitors targeting HIV envelope proteins].
Li MM; Xia CL; Mao QC; Jiang SB; Liu SW
Nan Fang Yi Ke Da Xue Xue Bao; 2010 May; 30(5):941-4. PubMed ID: 20501362
[TBL] [Abstract][Full Text] [Related]
17. A novel HIV-1 antiviral high throughput screening approach for the discovery of HIV-1 inhibitors.
Blair WS; Isaacson J; Li X; Cao J; Peng Q; Kong GF; Patick AK
Antiviral Res; 2005 Feb; 65(2):107-16. PubMed ID: 15708637
[TBL] [Abstract][Full Text] [Related]
18. Discordance between genotypic resistance and pseudovirus phenotypic resistance in AIDS patients after long-term antiretroviral therapy and virological failure.
Yang J; Geng W; Zhang M; Han X; Shang H
J Basic Microbiol; 2014 Oct; 54(10):1120-5. PubMed ID: 24338739
[TBL] [Abstract][Full Text] [Related]
19. [Virtual screening of small molecular HIV-1 entry inhibitor NC-2 targeting gp120 and its action mechanism].
Duan H; Wang Y; Song D; Chen Z; Qiu J; Lu L; Jiang S; Liu S; Tan S
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jun; 33(6):826-31. PubMed ID: 23803191
[TBL] [Abstract][Full Text] [Related]
20. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
Balzarini J; De Clercq E; Carbonez A; Burt V; Kleim JP
AIDS Res Hum Retroviruses; 2000 Apr; 16(6):517-28. PubMed ID: 10777142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
